Brainify.AI
Brainify.AI is a small business founded in 2021, headquartered in New York, specializing in mental health care through its AI biomarker platform aimed at improving depression treatments. The company is part of J&J Jlabs and Merck DSS, and has published over 100 articles in high-impact journals, backed by notable investors.
Company Overview
Brainify.AI operates within the Mental Health Care industry and was founded in 2021. The company is classified as a small business with a team size of 12. It is headquartered in New York, New York, USA. Brainify.AI focuses on developing an AI biomarker platform aimed at novel treatments for depression. The company is part of J&J Jlabs and Merck DSS, indicating its strong partnerships within the industry.
Technology and Innovation
The platform utilizes a Foundational EEG AI model that enhances treatment predictions and diagnostics in psychiatry, neurodegenerative disorders, and neurology. It is built on the largest EEG dataset globally, containing data from 120,000 patients and over 30 billion training data points. The model has been developed in-house using more than 14 million training segments and has been validated on separate clinical trial data. This technology aims to pioneer precision neuroscience by transforming raw EEG data into actionable insights.
Research and Publications
Brainify.AI has published over 100 articles in high-impact journals and conferences, showcasing its commitment to advancing research in mental health care. The platform's dataset is 95% private, and it automates the collection, integration, and standardization of diverse brain data from various sources, including clinics, pharmaceutical companies, and research institutions. This approach addresses the complexity and fragmentation of brain data, which can hinder advancements in neuroscience.
Partnerships and Funding
The company has established significant partnerships with J&J Labs and Merck DSS, which enhance its credibility and reach within the mental health care sector. Brainify.AI is backed by prominent investors, including Merck GHI Fund, Northpond, and Kodori VC. These partnerships and funding sources support the company's mission to develop innovative AI-driven solutions for mental health treatments.
Patents and Intellectual Property
Brainify.AI has secured four patents related to its technology, with several more in progress. These patents protect the company's innovations in AI biomarker development and treatment prediction. The Foundational AI model's ability to identify biomarkers for treatment response and diagnostics is a key focus of its intellectual property strategy.